We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-6.36%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.58B
AUM Growth
-$367M
Cap. Flow
-$23.4M
Cap. Flow %
-1.48%
Top 10 Hldgs %
42.1%
Holding
79
New
5
Increased
1
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$14.7M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$7.59M
3
ASND icon
Ascendis Pharma A/S
ASND
+$6.6M
4
ETNB
89bio
ETNB
+$4.23M
5
COGT icon
Cogent Biosciences
COGT
+$2.9M

Top Sells

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$24.6M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$14.5M
4
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$5.55M
5
GNCA
Genocea Biosciences, Inc.
GNCA
+$1.42M

Sector Composition

Rank Sector Weight
1 Healthcare 96.9%
2 Financials 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
26
Iovance Biotherapeutics
IOVA
$1.82B
$21.4M 1.35%
1,935,133
– –
DAWN
27
DELISTED
Day One Biopharmaceuticals
DAWN
$21.3M 1.35%
1,189,943
– –
GOSS icon
28
Gossamer Bio
GOSS
$82.9M
$20.6M 1.31%
2,462,358
– –
RCKT icon
29
Rocket Pharmaceuticals
RCKT
$340M
$20.2M 1.28%
1,466,051
– –
XENE icon
30
Xenon Pharmaceuticals
XENE
$6.06B
$18.3M 1.16%
600,000
– –
ACAD icon
31
Acadia Pharmaceuticals
ACAD
$4.43B
$17.8M 1.13%
1,263,930
– –
PNT
32
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$17M 1.08%
2,500,000
– –
NUVL
33
DELISTED
Nuvalent
NUVL
$16.4M 1.04%
1,210,192
– –
RNAM
34
DELISTED
Avidity Biosciences
RNAM
$16.3M 1.03%
1,121,327
– –
NRIX icon
35
Nurix Therapeutics
NRIX
$2.41B
$15.5M 0.98%
1,224,892
– –
SRPT icon
36
Sarepta Therapeutics
SRPT
$1.57B
$15M 0.95%
+200,000
New +$14.7M
BMEA icon
37
Biomea Fusion
BMEA
$84.6M
$14.2M 0.9%
1,188,405
– –
NUVB icon
38
Nuvation Bio
NUVB
$2.2B
$14.1M 0.89%
4,341,009
– –
CGEM icon
39
Cullinan Oncology
CGEM
$1.01B
$13.8M 0.87%
1,074,082
– –
MIST icon
40
Milestone Pharmaceuticals
MIST
$138M
$13.8M 0.87%
2,238,861
– –
FATE icon
41
Fate Therapeutics
FATE
$286M
$12.4M 0.78%
500,000
– –
GHRS icon
42
GH Research
GHRS
$1.93B
$10.1M 0.64%
1,013,399
– –
PRTA icon
43
Prothena Corp
PRTA
$425M
$8.14M 0.52%
300,000
– –
AKRO
44
DELISTED
Akero Therapeutics
AKRO
$7.86M 0.5%
831,495
– –
RAIN
45
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$6.53M 0.41%
1,175,000
– –
ASND icon
46
Ascendis Pharma A/S
ASND
$16B
$6.51M 0.41%
+70,000
New +$6.6M
NGM
47
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$6.41M 0.41%
500,000
– –
CNTA
48
DELISTED
Centessa Pharmaceuticals
CNTA
$6.09M 0.39%
1,251,137
– –
TSVT
49
DELISTED
2seventy bio
TSVT
$6.07M 0.38%
459,836
– –
DBVT
50
DBV Technologies
DBVT
$799M
$5.44M 0.34%
213,460
– –
1
2
3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Boxer Capital held 79 positions worth $1.58B, down 19% from $1.95B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Boxer Capital's Q2 2022 filing shows 5 new, 1 increased, 2 reduced and 3 closed positions. Its largest new stake was Sarepta Therapeutics: 200,000 shares worth $15M. The largest sale was iTeos Therapeutics, an estimated $24.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q2 2022 buy was Sarepta Therapeutics: 200,000 shares worth $15M.
  • Boxer Capital added most to Turning Point Therapeutics, Inc. Common Stock in Q2 2022, an estimated $7.59M increase.
  • Boxer Capital's biggest Q2 2022 reduction was iTeos Therapeutics, cutting an estimated $24.6M.
  • Boxer Capital fully exited Ultragenyx Pharmaceutical in Q2 2022, selling an estimated $14.5M.
  • Boxer Capital's ten largest holdings make up 42% of its $1.58B portfolio in Q2 2022.
  • Boxer Capital opened 5 new positions and closed 3 in Q2 2022.
  • Boxer Capital's portfolio value fell 19% quarter-over-quarter to $1.58B.

Based on Boxer Capital's 13F filing for Q2 2022, filed 15 Aug 2022.